Regulatory concerns encompass issues agencies like the FDA or EMA consider when evaluating AI use, including reliability, transparency, data governance and post‑market monitoring. Non‑specialist clinicians and managers must understand that these are not abstract worries: unresolved regulatory concerns can delay approvals, restrict use, or require substantial modifications to AI‑enabled products already embedded in research or clinical pathways.